Oral pulse therapy with vitamin D3 for control of secondary hyperparathyroidism

Hebrew University-Hadassah Medical School
Pediatric Nephrology (Impact Factor: 2.86). 11/1994; 8(6):724-726. DOI: 10.1007/BF00869102


Twelve dialysis patients received oral pulse therapy with 1--hydroxyvitamin D3 in a dose of 0.1 g/kg body weight twice weekly and daily calcium carbonate (1.5–3.5 g) for a period of 8–12 months. This treatment was very effective in suppressing secondary hyperparathyroidism without causing hypercalcaemia and/or hyperphosphataemia.

0 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To review the medical literature on management of end-stage renal disease (ESRD) and its complications in the pediatric patient. MEDLINE searches (1970-1997) of the English-language literature. Clinical trials and reviews of drug therapy management were included, and bibliographies were reviewed for relevant articles. Principles of renal replacement therapy in children have been expanded to include maintenance of fluid and electrolyte balance and to manage the complications of ESRD in children. Types of renal replacement and their complications are reviewed. Complications of ESRD are reviewed with emphasis on drug therapy management of anemia of chronic renal failure, growth retardation, and hypertension. A discussion of the use of vitamins and supplements to maintain bone and mineral homeostasis is provided, and specific recommendations for vaccination of children with ESRD are given. Children with end-stage renal failure present a unique challenge to the pharmacist. Renal replacement therapy for children with ESRD involves some form of dialysis and an intensive medication regimen. Complications must be treated with appropriate drug therapy. Drug therapy must be monitored closely for dosage adjustment, clinical response, drug interactions, and toxicity. Patients and families must receive continuous education and follow-up to encourage compliance. The pharmacist must work closely with the healthcare team to optimize drug therapy and improve patient education and compliance.
    Annals of Pharmacotherapy 10/1998; 32(9):929-39. DOI:10.1345/aph.17369 · 2.06 Impact Factor